ArticleThe Journal of experimental medicine2017
Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction.
Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta-analysis.Clinical and translational science · 2021Pooled it
- PVNAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Urocortin2 measurement for heart failure assessment.Scientific reports · 2025Article
- By what molecular mechanisms do social determinants impact cardiometabolic risk?Clinical science (London, England : 1979) · 2023Review
- Article
- Circulating levels of urocortin neuropeptides are impaired in children with overweight.Obesity (Silver Spring, Md.) · 2022Article
- Transcriptome and morphological analysis on the heart in gestational protein-restricted aging male rat offspring.Frontiers in cell and developmental biology · 2022Article
- Uric Acid Predicts Recovery of Left Ventricular Function and Adverse Events in Heart Failure With Reduced Ejection Fraction: Potential Mechanistic Insight From Network Analyses.Frontiers in cardiovascular medicine · 2022Article
- Urocortin Role in Ischemia Cardioprotection and the Adverse Cardiac Remodeling.International journal of molecular sciences · 2021Review
- Transcriptome-Based Analysis Reveals Therapeutic Effects of Resveratrol on Endometriosis in aRat Model.Drug design, development and therapy · 2021Article
- β-Adrenergic receptor, an essential target in cardiovascular diseases.Heart failure reviews · 2020Review
- Evaluation of Serum Urocortin 2 Levels in Patients with Hypertension.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2020Article
- Long-term UVA exposure to the eye compromises memory and learning ability in mice via corticotropin-releasing hormone type 2 receptor.International journal of biological sciences · 2020Article
- Study on the Differences between Traditional Chinese Medicine Syndromes in NYHA I-IV Classification of Chronic Heart Failure.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Sexually dimorphic metabolic responses mediated by CRFBiology of sex differences · 2018Article
- Structural and functional cardiac profile after prolonged duration of mechanical unloading: potential implications for myocardial recovery.American journal of physiology. Heart and circulatory physiology · 2018Article
- Designer Approaches for G Protein-Coupled Receptor Modulation for Cardiovascular Disease.JACC. Basic to translational science · 2018Review
- Urocortin 2: will a drug targeting both the vasculature and the right ventricle be the future of pulmonary hypertension therapy?Cardiovascular research · 2018Article
- Cardiovascular disease: CRHR2 blockade prevents heart failure.Nature reviews. Drug discovery · 2017Article
- Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure occurs when the heart is unable to effectively pump blood and maintain tissue perfusion. Despite numerous therapeutic advancements over previous decades, the prognosis of patients with chronic heart failure remains poor, emphasizing the need to identify additional pathophysiological factors. Here, we show that corticotropin releasing hormone receptor 2 (Crhr2) is a G protein-coupled receptor highly expressed in cardiomyocytes and continuous infusion of the Crhr2 agonist, urocortin 2 (Ucn2), reduced left ventricular ejection fraction in mice. Moreover, plasma Ucn2 levels were 7.5-fold higher in patients with heart failure compared to those in healthy controls. Additionally, cardiomyocyte-specific deletion of Crhr2 protected mice from pressure overload-induced cardiac dysfunction. Mice treated with a Crhr2 antagonist lost maladaptive 3'-5'-cyclic adenosine monophosphate (cAMP)-dependent signaling and did not develop heart failure in response to overload. Collectively, our results indicate that constitutive Crhr2 activation causes cardiac dysfunction and suggests that Crhr2 blockade is a promising therapeutic strategy for patients with chronic heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.